(05-02-16) The effect of statins on average survival in randomised trials, an analysis of end point postponement

1. Malene Lopez Kristensen1,
2. Palle Mark Christensen1,
3. Jesper Hallas1,2
+ Author Affiliations
1. 1Department of Clinical Pharmacology, University of Southern Denmark, Odense, Denmark
2. 2Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark
1. Correspondence to Professor Jesper Hallas; [email protected]
Received 21 November 2014
Revised 29 April 2015
Accepted 7 May 2015
Published 24 September 2015
Abstract
Objective To estimate the average postponement of death in statin trials.
Setting A systematic literature review of all statin trials that presented all-cause survival curves for treated and untreated.
Intervention Statin treatment compared to placebo.
Primary outcome measures The average postponement of death as represented by the area between the survival curves.
Results 6 studies for primary prevention and 5 for secondary prevention with a follow-up between 2.0 and 6.1 years were identified. Death was postponed between −5 and 19 days in primary prevention trials and between −10 and 27 days in secondary prevention trials. The median postponement of death for primary and secondary prevention trials were 3.2 and 4.1 days, respectively.
Conclusions Statin treatment results in a surprisingly small average gain in overall survival within the trials’ running time. For patients whose life expectancy is limited or who have adverse effects of treatment, withholding statin therapy should be considered.


Source: BMJ Open 2015;5:e007118 doi:10.1136/bmjopen-2014-007118

News

---

In evidenza

"L'informazione presente nel sito serve a migliorare, e non a sostituire, il rapporto medico-paziente."

Per coloro che hanno problemi di salute si consiglia di consultare sempre il proprio medico curante.